Document Type : Review Article(s)
Author
School of Nursing, Hashemite University, Az Zarqa, Jordan
Abstract
Antiemetics are given to cancer patients prior to their chemotherapy sessions to protect them from nausea and vomiting induced by chemotherapy. The responsible health care team member will choose the type of antiemetic required to prevent the patient from developing nausea and vomiting according to the chemotherapy ematogenicity level. Current guidelines recommend using a single antiemetic agent or a combination of antiemetic agents such as a 5-hydroxytrypt-amine3 receptor antagonist, dexamethasone, or the neurokinin-1 receptor antagonist aprepitant. This review discusses the role of aprepitant in preventing and managing nausea and vomiting induced by chemotherapy.
)